Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 13;10(6):938.
doi: 10.3390/vaccines10060938.

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

Andrey S Shkoda  1 , Vladimir A Gushchin  2   3 , Darya A Ogarkova  2 , Svetlana V Stavitskaya  1 , Olga E Orlova  1 , Nadezhda A Kuznetsova  2 , Elena N Keruntu  1 , Andrei A Pochtovyi  2   3 , Alexander V Pukhov  1 , Denis A Kleymenov  2 , Vasyli G Krzhanovsky  1 , Daria V Vasina  2 , Nataliya V Shkuratova  1 , Elena V Shidlovskaya  2 , Alexey L Gorbunov  1 , Daria D Kustova  2   3 , Evgeniya A Mazurina  1 , Sofya R Kozlova  2 , Alexandra V Soboleva  1 , Igor V Grigoriev  2 , Lyudmila L Pankratyeva  1 , Alina S Odintsova  2 , Elizaveta D Belyaeva  2   3 , Arina A Bessonova  2 , Lyudmila A Vasilchenko  2 , Igor P Lupu  2 , Ruslan R Adgamov  2 , Artem P Tkachuk  2 , Elizaveta A Tokarskaya  2 , Denis Y Logunov  2 , Alexander L Gintsburg  2   4
Affiliations

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

Andrey S Shkoda et al. Vaccines (Basel). .

Abstract

Mass vaccination campaigns against COVID-19 affected more than 90% of the population in most developed countries. The new epidemiologic wave of COVID-19 has been ongoing since the end of 2021. It is caused by a virus variant B.1.1.529, also known as "Omicron" and its descendants. The effectiveness of major vaccines against Omicron is not known. The purpose of this study is to evaluate the efficacy of the Sputnik V vaccine. The main goal is to assess its protection against hospitalization in the period of Omicron dominance. We conducted our study based on a large clinical center in Moscow (Russia) where 1112 patients were included. We used the case-population method to perform the calculations. The data we obtained indicate that the Omicron variant causes at least 90% of infections in the studied cohort. The effectiveness of protection against hospitalization with COVID-19 in our study was 85.9% (95% CI 83.0-88.0%) for those who received more than one dose. It was 87.6% (95% CI 85.4-89.5%) and 97.0% (95% CI 95.9-97.8%) for those who received more than two or three doses. The effectiveness in cases of more severe forms was higher than for less severe ones. Thus, present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage.

Keywords: COVID-19; Omicron; SARS-CoV-2; Sputnik Light; Sputnik V; VOC; vaccine; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

D.Y.L. and A.L.G. (Alexander L. Gintsburg) report patents for a Sputnik V immunobiological expression vector, for a pharmaceutical agent, and for its method of use to prevent COVID-19. The funders had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; in the preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Viral load (copies/mL) depending on the severity of the disease and the strain. (A) Omicron strain; (B) Delta strain.
Figure 2
Figure 2
Levels of IgG antibodies in the RBD domain and NC protein depending on severity. Two groups are presented—unvaccinated and vaccinated with two components of Sputnik V. The Y-axis indicates the number of antibodies (PC), and shows the median, upper, and lower quantiles. The unvaccinated samples are characterized by a wide variation in the level of IgG antibodies in the RBD domain of the S protein. (A)—shows the level of antibodies IgG RBD in unvaccinated patients, (B)—the level of IgG NC in unvaccinated patients, (C)—the level of IgG RBD in vaccinated patient and (D)—the level of IgG NC in vaccinated patients.
Figure 3
Figure 3
Effectiveness of vaccination in relation to the varying severity of the disease among hospitalized patients, considering the number of vaccine doses received. (A) Protection from any cases of hospitalization, (B) protection from moderate-severe and more severe cases, (C) protection from severe and critical cases, and (D) protection from critical cases (VE 95% CI).
See this image and copyright information in PMC

References

    1. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., et al. Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet. 2021;397:671–681. doi: 10.1016/S0140-6736(21)00234-8. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. Butt A.A., Omer S.B., Yan P., Shaikh O.S., Mayr F.B. SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting. Ann. Intern. Med. 2021;174:1404–1408. doi: 10.7326/M21-1577. - DOI - PMC - PubMed

LinkOut - more resources